Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NHS-IL12||M9241||NHS-IL12 is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||NHS-IL12||Phase I||Actionable||In a Phase I trial, NHS-IL12 was well tolerated in patients with metastatic advanced solid tumors and resulted in stable disease in 50% (15/30) of patients with measurable disease, with durable stable disease in 5 patients (two prostate, one colorectal, one breast, and one chordoma) lasting more than 6 months (PMID: 30131389; NCT01417546).||30131389|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04303117||Phase Ib/II||NHS-IL12 M7824 + NHS-IL12||NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma||Recruiting|
|NCT01417546||Phase I||NHS-IL12||NHS-IL12 for Solid Tumors||Recruiting|